Literature DB >> 11030885

Lymphatic involvement in early gastric cancer: prevalence and prognosis in France.

F Borie1, B Millat, A Fingerhut, J M Hay, P L Fagniez, B De Saxce.   

Abstract

BACKGROUND: The prognosis of early gastric cancer (EGC) is considered better than that of invasive gastric carcinoma, with a 5-year survival rate of more than 90% after surgery. The prevalence of lymph node metastasis in EGC ranges from 8% to 20% and is associated with a poor prognosis. HYPOTHESIS: The main prognostic factor of EGC in patients in France is lymphatic involvement. DESIGN, SETTING, AND PATIENTS: From January 1979 to December 1988, 332 patients with EGC were operated on in 23 centers of 2 of the French Associations for Surgical Research. Clinical, pathological, and therapeutic data were reviewed, and the reckoning point was in June 1996. MAIN OUTCOME MEASURES: The cumulative 5- and 7-year specific survival rates of EGC with or without lymphatic involvement.
RESULTS: The cumulative 5- and 7-year specific survival rates of 332 patients with EGC (mean follow-up time, 80 months), excluding both operative and unrelated mortality, were 92% and 87.5%, respectively. Thirty-four patients (10.2%) had metastatic lymphatic spread: 13 exclusively in the lymphatic vessels close to the tumor, 17 in at least 1 lymph node, and 4 in both the lymphatic vessels and nodes. The rate of lymph node involvement (regardless of lymphatic vessel involvement) correlated significantly with submucosal invasion (P =. 05) and histologic undifferentiation (P =.03). Lymphatic vessel involvement correlated positively with lymph node involvement (P =. 003). Since 5- and 7-year survival rates of the 13 patients with EGC who had lymphatic vessel involvement without lymph node involvement did not differ significantly from those of patients who had EGC with lymph node involvement (85% and 84% vs 72% and 63%, respectively [P =.42]), all patients with lymph node and/or lymphatic vessel involvement were considered unique. Prognosis was poorest in these patients according to both univariate analysis (94% for 298 without node or vessel involvement vs 78% for 34 with node and/or vessel involvement; P =.006) and multivariate analysis (P =.01). Submucosal invasion was a prognostic factor independent of lymphatic involvement (P =.05). Five- and 7-year survival rates did not differ when the group of 211 patients for whom less than 15 lymph nodes were retrieved were compared with those (n = 51) for whom 15 or more lymph nodes were retrieved (95.5% vs 92% and 95.5% vs 88%, respectively), whether according to univariate (P =.21) or multivariate (P =.31) analysis.
CONCLUSIONS: Our results suggest that both lymph node and lymphatic vessel involvement are important prognostic factors in patients with EGC. Lymphadenectomy in EGC is important to identify the high-risk population for whom prognosis is worse. The extent of lymphadenectomy (at least 15 nodes) in these patients, however, does not alter prognosis.

Entities:  

Mesh:

Year:  2000        PMID: 11030885     DOI: 10.1001/archsurg.135.10.1218

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  29 in total

1.  Confirmation of the posterior gastric artery using multi-detector row computed tomography.

Authors:  Takehiro Okabayashi; Michiya Kobayashi; Satoshi Morishita; Takeki Sugimoto; Toyokazu Akimori; Tsutomu Namikawa; Ken Okamoto; Norihiro Hokimoto; Keijiro Araki
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

Review 2.  Redefining early gastric cancer.

Authors:  Savio G Barreto; John A Windsor
Journal:  Surg Endosc       Date:  2015-04-01       Impact factor: 4.584

3.  Is It Reasonable to Treat Early Gastric Cancer with Mucosal Infiltration and Well Differentiation by Endoscopic Submucosal Resection?

Authors:  Fan Feng; Li Sun; Guanghui Xu; Lei Cai; Liu Hong; Jianjun Yang; Man Guo; Xiao Lian; Hongwei Zhang
Journal:  J Gastrointest Surg       Date:  2015-09-10       Impact factor: 3.452

4.  Risk factors for submucosal and lymphovascular invasion in gastric cancer looking indicative for endoscopic submucosal dissection.

Authors:  Takeshi Yamada; Hiroaki Sugiyama; Daisuke Ochi; Daisuke Akutsu; Hideo Suzuki; Toshiaki Narasaka; Toshikazu Moriwaki; Shinji Endo; Tsuyoshi Kaneko; Kaishi Satomi; Kazuto Ikezawa; Yuji Mizokami; Ichinosuke Hyodo
Journal:  Gastric Cancer       Date:  2013-12-10       Impact factor: 7.370

5.  Predictors of Lymph Node Metastasis in Western Early Gastric Cancer.

Authors:  Rima Ahmad; Namrata Setia; Benjamin H Schmidt; Theodore S Hong; Jennifer Y Wo; Eunice L Kwak; David W Rattner; Gregory Y Lauwers; John T Mullen
Journal:  J Gastrointest Surg       Date:  2015-09-18       Impact factor: 3.452

6.  Clinicopathological features associated with lymph node metastasis in early gastric cancer: analysis of a single-institution experience in China.

Authors:  Lizong Shen; Yiming Huang; Maocai Sun; Hao Xu; Wei Wei; Wenxi Wu
Journal:  Can J Gastroenterol       Date:  2009-05       Impact factor: 3.522

7.  Prediction of the indication criteria for endoscopic resection of early gastric cancer.

Authors:  Jae Hyun Park; Si Hyung Lee; Joon Mo Park; Chan Seo Park; Kyung Sik Park; Eun Soo Kim; Kwang Bum Cho
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

8.  Prediction of risk factors for lymph node metastasis in early gastric cancer.

Authors:  Gang Ren; Rong Cai; Wen-Jie Zhang; Jin-Ming Ou; Ye-Ning Jin; Wen-Hua Li
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

9.  Predictive factors for recurrence in T2N0 and T3N0 gastric cancer patients.

Authors:  Hiroaki Saito; Yuki Murakami; Kozo Miyatani; Hirohiko Kuroda; Tomoyuki Matsunaga; Yoji Fukumoto; Tomohiro Osaki; Masahide Ikeguchi
Journal:  Langenbecks Arch Surg       Date:  2016-07-27       Impact factor: 3.445

10.  Survival after surgical treatment of early gastric cancer, surgical techniques, and long-term survival.

Authors:  Norihiro Yuasa; Yuji Nimura
Journal:  Langenbecks Arch Surg       Date:  2004-04-30       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.